Close menu




April 7th, 2021 | 09:10 CEST

Palantir, wallstreet:online, NanoRepro - Profit from the correction!

  • Investments
Photo credits: pixabay.com

The correction in most technology stocks last month was short and painful. Stocks in sectors that have been hyped in recent months, such as hydrogen, electromobility and e-commerce, lost more than half of their market value at their peak. The most important price barometer for high-tech stocks, the Nasdaq 100, corrected from over 13,800 points to just under 12,200 points at its low. Since then, a dynamic countermovement has set in, which should soon lead to new highs. Take your chance now to invest in attractive stocks!

time to read: 3 minutes | Author: Stefan Feulner
ISIN: US69608A1088 , DE000A2GS609 , DE0006577109

Table of contents:


    wallstreet:online - In the midst of growth

    One of the winners of the Corona Crisis were online brokers. Many people, especially the younger adults, used #WirbleibenzuHause to get involved with shares, funds, ETFs and Co. According to the German Stock Institute, there were 28% more shareholders in 2020 than the year before. Especially among those under 30, stocks seem to be right on trend at the moment. A total of 600,000 young adults ventured into the market, an increase of almost 70% compared to the previous year. In addition to the pandemic, neobrokers, with their mobile-first strategy, were the main reason a new generation of investors established itself in the capital market.

    In the mobile sector, Smartbroker, founded in 2019 and belonging to wallstreet:online AG wants to catch up with the neobrokers. Through an innovative smartphone app, the Berliners wish to increase both customer growth and transactions made significantly. Thus, the number of customer deposits is expected to increase by 120,000 to 200,000 this year. Despite the rapidly growing portal business - wallstreet:online is the absolute market leader with sites such as wallstreet-online.de, finanznachrichten.de and ariva.de - Smartbroker is set to become the growth driver of the future. As early as 2021, 40% of the Group's total revenue is to be generated from the transactional business and around 60% from advertising income.

    The analysts at GBC AG expect wallstreet:online AG to generate an EBITDA of almost EUR 20 million in 2021 and see the stock as a buy candidate with a price target of EUR 29. Currently, the share price is still in the consolidation phase and is quoted at EUR 18.70 after the all-time high of EUR 29.70 in mid-February. The bottoming phase will be completed once the resistance at EUR 21 has been overcome. In the long term, the growth stock offers good opportunities for above-average returns.

    Palantir - Buy the dip!

    Rarely do investor opinions differ as strongly as they do with the US data analysis Company Palantir Technologies' stock. For some, it is the next big thing after Tesla, and for others, it is far too expensive and too opaque. On "WallStreetBets," a forum on the Reddit community, Palantir even overtook GameStop as the "most discussed stock" at times. The US Company, which lost more than 30% of its value in recent weeks due to its weaker-than-expected quarterly figures and the end of the lock-up period for existing shareholders, was now able to announce another significant government contract.

    The Company has signed a five-year contract worth USD 89.9 million with the National Nuclear Security Administration NNSA, part of the United States Department of Energy. In return, Palantir will provide digital security and analytics capabilities for an NNSA nuclear security project. Under the terms of the contract, NNSA will use Palantir for "effective knowledge management and data-driven decision making" as part of a more extensive security, analytics, forecasting and evaluation reporting project, also known as SAFER.

    The positive news sent shares trading up as much as 4% to the current USD 23.44. From a chart perspective, a sustained break above the USD 25 mark would be a liberating blow.

    NanoRepro - The winner of a sustainable trend

    Being in the right place at the right time is especially true for NanoRepro AG. Before Corona, the Marburg-based Company was active in the field of self-diagnostics and had 25 rapid tests in its portfolio - including an HIV test, two pregnancy tests and five others purely for medical use. Corona and its entry into the field of rapid antigen tests rewrote the Company's history.

    CFO Stefan Pieh has released forecasts for 2021. This sees at least EUR 250 million sales volume based on Corona's B2B rapid antigen tests to date and its partnership with ViroMed. Possible larger orders from abroad or orders in the currently not yet approved saliva test for the end customer area are only included to a small extent in this scenario.

    Overall, a sales volume of EUR 400 million is possible. In addition to its operational activities, which are currently strongly focused on the sale of Corona's rapid antigen tests, NanoRepro is presently evaluating several promising products from the medical/healthcare sector for the expansion of its business base after "Corona." In our opinion, NanoRepro's business model with Corona rapid tests should continue for a long time. Life without a mask and testing seems unlikely at the moment, even after the virus has been contained. One should use more significant setbacks to enter the share.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read